Haemonetics (NYSE:HAE) is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.
The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies. Haemonetics’ software platforms streamline donor recruitment, inventory management and transfusion workflows, while its disposables and clinical support services help minimize waste and ensure compliance with regulatory standards. Key innovations such as the TEG® Hemostasis Analyzer and INTERCEPT® Blood System have earned recognition for improving patient outcomes and reducing risks associated with transfusion therapy.
Founded in 1971 and headquartered in Braintree, Massachusetts, Haemonetics has grown through a combination of organic innovation and targeted acquisitions. The company maintains a global footprint, operating in North America, Europe, Asia-Pacific and Latin America through a network of subsidiaries, manufacturing facilities and distribution partners. This international presence enables Haemonetics to adapt its technologies to local regulatory requirements and healthcare practices.
Under the leadership of President and Chief Executive Officer Chris Simon, Haemonetics is advancing its strategy to integrate digital analytics and expand its consumables business. With a focus on research and development, the company continues to pursue collaborations with clinical customers and technology partners to address emerging challenges in blood management and transfusion safety.
